The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM) - PubMed (original) (raw)
Review
. 2013 May-Jun;27(3):280-6.
doi: 10.1016/j.jdiacomp.2012.12.004. Epub 2013 Feb 1.
Affiliations
- PMID: 23375850
- DOI: 10.1016/j.jdiacomp.2012.12.004
Review
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
Jan N Basile. J Diabetes Complications. 2013 May-Jun.
Abstract
Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV risk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
- Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P. Raskin P. Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403. Diabetes Metab Res Rev. 2013. PMID: 23463735 Review. - The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R, Inzucchi SE, Fioretto P. Vettor R, et al. Diabetologia. 2017 Mar;60(3):395-398. doi: 10.1007/s00125-016-4194-y. Epub 2017 Jan 11. Diabetologia. 2017. PMID: 28074254 No abstract available. - The EMPA-REG study: What has it told us? A diabetologist's perspective.
DeFronzo RA. DeFronzo RA. J Diabetes Complications. 2016 Jan-Feb;30(1):1-2. doi: 10.1016/j.jdiacomp.2015.10.013. Epub 2015 Oct 21. J Diabetes Complications. 2016. PMID: 26541076 Free PMC article. No abstract available. - Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ. Bailey CJ. Trends Pharmacol Sci. 2011 Feb;32(2):63-71. doi: 10.1016/j.tips.2010.11.011. Epub 2011 Jan 4. Trends Pharmacol Sci. 2011. PMID: 21211857 Review. - Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M. DeFronzo RA, et al. Diabetes Obes Metab. 2016 May;18(5):454-62. doi: 10.1111/dom.12652. Epub 2016 Apr 6. Diabetes Obes Metab. 2016. PMID: 26919068 Review.
Cited by
- Cardiovascular disease and risk factors in adults with diabetes mellitus in Hungary: a population-based study.
Ulambayar B, Ghanem AS, Kovács N, Trefán L, Móré M, Nagy AC. Ulambayar B, et al. Front Endocrinol (Lausanne). 2023 Sep 14;14:1263365. doi: 10.3389/fendo.2023.1263365. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37780630 Free PMC article. - New Insights into the Use of Empagliflozin-A Comprehensive Review.
Forycka J, Hajdys J, Krzemińska J, Wilczopolski P, Wronka M, Młynarska E, Rysz J, Franczyk B. Forycka J, et al. Biomedicines. 2022 Dec 19;10(12):3294. doi: 10.3390/biomedicines10123294. Biomedicines. 2022. PMID: 36552050 Free PMC article. Review. - Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review.
Thakur M, Sangha PS, Satti A, Shah PN. Thakur M, et al. Cureus. 2020 Oct 14;12(10):e10942. doi: 10.7759/cureus.10942. Cureus. 2020. PMID: 33200056 Free PMC article. Review. - National ambulatory care non-insulin antidiabetic medication prescribing trends in the United States from 2009 to 2015.
Kitten AK, Kamath M, Ryan L, Reveles KR. Kitten AK, et al. PLoS One. 2019 Aug 14;14(8):e0221174. doi: 10.1371/journal.pone.0221174. eCollection 2019. PLoS One. 2019. PMID: 31412090 Free PMC article. - SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E. Kyriakos G, et al. Curr Cardiol Rev. 2020;16(4):258-265. doi: 10.2174/1573403X15666190730094215. Curr Cardiol Rev. 2020. PMID: 31362691 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical